Company Information
AIM rule 26
The following information is provided for AIM rule 26 compliance and was last reviewed in February 2023.
Description of the Business: A description can be found via the following link
https://www.ekfdiagnostics.com/Investors.html
Board of Directors: Names and biographies can be found via the following link
https://www.ekfdiagnostics.com/investors-directors-advisors.html
Directors Responsibilities: These and details of any board committees and their responsibilities can be found via the following link
https://www.ekfdiagnostics.com/corporate-governance-and-committees.html
Country of Incorporation: The Company is incorporated and domiciled in England and Wales.
Main Countries of Operation: United Kingdom, Germany, Russia and USA
Company Documents: The Company’s Admission document, ciruclars and other constitutional documents can be found via the following link
https://www.ekfdiagnostics.com/documents-reports.html
Annual Accounts: The Company’s most recent and historical Annual Report and Accounts can be found via the following link
https://www.ekfdiagnostics.com/documents-reports.html
Regulatory News: All Company announcements can be found via the following link
https://www.ekfdiagnostics.com/rns.html
Corporate Governance: The Company adopted the QCA Code and the details of its compliance can be found via the following link
https://www.ekfdiagnostics.com /corporate-governance-and-committees.html
Advisors: Details of nominated adviser and other key advisers can be found via the following link
https://www.ekfdiagnostics.com/investors-directors-advisors.html
TIDM: EKF
VAT number: 805940921
Date shares admitted for trading: 7th July 2010
Share information
Exchanges where quoted and traded: EKF Diagnostics securities are not traded on any exchanges or trading platforms other than AIM.
Number of AIM securities in issue: 454,930,564 shares are issued, called up and fully paid.
Percentage of securities not in public hands: As at 5th June 2023 percentage of AIM securities not in the public hands was 29.5%. The securities not in public hands include all substantial shareholders over 10%, the directors and senior management who are classed as persons discharging managerial responsibilities.
Restrictions on the transfer of securities: There is no restriction on the transfer of EKF Diagnostics Holdings plc securities.
Significant shareholders
|
Significant shareholders |
No. of ordinary shares | % held |
|
Harwood Capital |
132,150,000 |
29.13% |
|
Liontrust Asset Management |
50,000,638 |
11.02% |
| Gresham House | 46,088,498 | 10.16% |
|
Schroder Investment Mgt |
18,446,514 |
4.07% |
|
Stock Invest Limited |
18,555,500 |
4.09% |
Last updated 05 June 2023
Directors' shareholdings
| Shareholder | No. of ordinary shares | % held |
|
Christopher Mills* |
132,150,000 |
29.13% |
| Julian Baines | 1,616,288 | 0.36% |
*Christopher Mills is partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited. Christopher’s shareholding is made up of 96,000,000 ordinary shares held by North Atlantic Smaller Companies Investment Trust PLC, 36,000,000 ordinary shares are held by Oryx International Growth Fund Limited and 150,000 ordinary shares are held by Christopher Mills
Last updated 05 June 2023
Company details
Registered address and Head Office:
EKF Diagnostics Holdings plc
Avon House,
19 Stanwell Road
Penarth
Cardiff
CF64 2EZ
Company registration number:
04347937
VAT number:
805940921
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.